Sang‐We Kim

21.5k total citations · 5 hit papers
207 papers, 5.4k citations indexed

About

Sang‐We Kim is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Sang‐We Kim has authored 207 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 161 papers in Pulmonary and Respiratory Medicine, 148 papers in Oncology and 42 papers in Molecular Biology. Recurrent topics in Sang‐We Kim's work include Lung Cancer Treatments and Mutations (139 papers), Lung Cancer Research Studies (77 papers) and Lung Cancer Diagnosis and Treatment (43 papers). Sang‐We Kim is often cited by papers focused on Lung Cancer Treatments and Mutations (139 papers), Lung Cancer Research Studies (77 papers) and Lung Cancer Diagnosis and Treatment (43 papers). Sang‐We Kim collaborates with scholars based in South Korea, United States and Taiwan. Sang‐We Kim's co-authors include Myung‐Ju Ahn, Jung‐Shin Lee, Dae Ho Lee, Dong‐Wan Kim, Keunchil Park, Dae Ho Lee, Cheolwon Suh, Ji‐Youn Han, James Chih‐Hsin Yang and Cheolwon Suh and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Sang‐We Kim

201 papers receiving 5.3k citations

Hit Papers

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemci... 2012 2026 2016 2021 2012 2017 2022 2021 2022 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
    2012 611 citations Ji‐Youn Han, Sang‐We Kim et al. Journal of Clinical Oncology profile →
  2. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
    2017 430 citations Dong‐Wan Kim, Myung‐Ju Ahn et al. Journal of Clinical Oncology profile →
  3. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
    2022 238 citations Melissa L. Johnson, Byoung Chul Cho et al. Journal of Clinical Oncology profile →
  4. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
    2021 196 citations Suresh S. Ramalingam, Tae Min Kim et al. profile →
  5. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON
    2022 95 citations Ryan J. Hartmaier, Aleksandra Markovets et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sang‐We Kim South Korea 36 3.9k 3.5k 1.4k 743 382 207 5.4k
Lowell L. Hart United States 37 2.2k 0.6× 3.5k 1.0× 1.7k 1.2× 763 1.0× 480 1.3× 127 5.5k
Hiroshi Nokihara Japan 40 3.3k 0.9× 3.9k 1.1× 1.7k 1.2× 935 1.3× 330 0.9× 237 5.9k
Renato Martins United States 20 4.7k 1.2× 4.6k 1.3× 1.7k 1.2× 916 1.2× 302 0.8× 42 6.7k
Mircea Dediu Romania 19 5.1k 1.3× 4.8k 1.4× 1.6k 1.1× 894 1.2× 289 0.8× 55 6.6k
M. Pérol France 33 5.4k 1.4× 4.7k 1.3× 1.5k 1.1× 1.3k 1.7× 506 1.3× 292 7.0k
Wilfried Eberhardt Germany 39 5.3k 1.4× 4.2k 1.2× 1.7k 1.2× 892 1.2× 369 1.0× 239 7.6k
Haruyasu Murakami Japan 40 3.7k 0.9× 3.8k 1.1× 1.4k 1.0× 908 1.2× 284 0.7× 306 6.1k
Eng Huat Tan Singapore 22 4.7k 1.2× 4.6k 1.3× 1.7k 1.2× 1.0k 1.4× 273 0.7× 55 6.8k
Mark S. Huberman United States 30 3.3k 0.8× 3.0k 0.9× 1.2k 0.9× 778 1.0× 353 0.9× 80 4.5k
Patrick M. Forde United States 40 2.7k 0.7× 4.0k 1.1× 934 0.7× 645 0.9× 348 0.9× 186 5.7k

Countries citing papers authored by Sang‐We Kim

Since Specialization
Citations

This map shows the geographic impact of Sang‐We Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sang‐We Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sang‐We Kim more than expected).

Fields of papers citing papers by Sang‐We Kim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sang‐We Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sang‐We Kim. The network helps show where Sang‐We Kim may publish in the future.

Co-authorship network of co-authors of Sang‐We Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Sang‐We Kim. A scholar is included among the top collaborators of Sang‐We Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sang‐We Kim. Sang‐We Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dingemans, Anne‐Marie C., Konstantinos Syrigos, Lorenzo Livi, et al.. (2025). Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial. Lung Cancer. 207. 108683–108683.
2.
Steuer, Conor, Hidetoshi Hayashi, Wu‐Chou Su, et al.. (2025). Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy. Journal of Clinical Oncology. 43(25). 2816–2826. 3 indexed citations
3.
Park, Sehhoon, Hyun Ae Jung, Jong‐Mu Sun, et al.. (2024). Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer (BLOSSOM). Journal of Clinical Oncology. 42(23). 2747–2756. 23 indexed citations
4.
Jänne, Pasi A., Toshio Kubo, Kiichiro Ninomiya, et al.. (2024). Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02.. Journal of Clinical Oncology. 42(16_suppl). 8543–8543. 4 indexed citations
5.
Lee, Jiyun, Hee Kyung Ahn, Sang‐We Kim, et al.. (2024). Real‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study. Cancer Medicine. 13(7). e7174–e7174. 1 indexed citations
6.
Kim, Dong‐Wan, Byoung Chul Cho, Sang‐We Kim, et al.. (2024). Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study. Lung Cancer. 190. 107530–107530. 5 indexed citations
7.
Cho, Byoung Chul, Ji‐Youn Han, Ki Hyeong Lee, et al.. (2024). Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201. Lung Cancer. 190. 107509–107509. 4 indexed citations
8.
Solomon, Benjamin, Ibiayi Dagogo‐Jack, Se-Hoon Lee, et al.. (2024). Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial. JTO Clinical and Research Reports. 5(7). 100685–100685. 1 indexed citations
9.
10.
Cho, Byoung Chul, Grace K. Dy, Tae Min Kim, et al.. (2023). PP.42 Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced NSCLC. Journal of Thoracic Oncology. 18(3). S25–S25. 1 indexed citations
11.
Garon, Edward B., Byoung Chul Cho, Alexander Luft, et al.. (2023). Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON). Lung Cancer. 186. 107422–107422. 4 indexed citations
12.
Hartmaier, Ryan J., Aleksandra Markovets, Myung‐Ju Ahn, et al.. (2022). Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON. Cancer Discovery. 13(1). 98–113. 95 indexed citations breakdown →
13.
Johnson, Melissa L., Byoung Chul Cho, Alexander Luft, et al.. (2022). Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study. Journal of Clinical Oncology. 41(6). 1213–1227. 238 indexed citations breakdown →
14.
Tan, Daniel S.W., Sang‐We Kim, Santiago Ponce Aix, et al.. (2022). Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study. European Journal of Cancer. 172. 276–286. 11 indexed citations
15.
Levy, Benjamin, Fabrice Barlési, Luis Paz‐Ares, et al.. (2022). Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). Lung Cancer. 166. 107–113. 6 indexed citations
16.
Park, Sojung, Tai Sun Park, Chang‐Min Choi, et al.. (2015). Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements. Clinical Lung Cancer. 16(5). e83–e89. 39 indexed citations
17.
Kim, Ho Cheol, Joon Seon Song, Jae Cheol Lee, et al.. (2014). Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer.. PubMed. 7(10). 6743–51. 9 indexed citations
18.
Sohn, Hee-Jung, Jin‐Sook Ryu, Seung Jun Oh, et al.. (2008). [18F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung. Clinical Cancer Research. 14(22). 7423–7429. 125 indexed citations
19.
Kim, Young Seok, Sang Min Yoon, Eun Kyung Choi, et al.. (2005). Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non–small-cell lung cancer. International Journal of Radiation Oncology*Biology*Physics. 62(1). 76–81. 31 indexed citations
20.
Sohn, Hee-Jung, Eun-Kyung Kim, Gyeong‐Won Lee, et al.. (2003). Survival according to Treatment Modalities in 137 Patients with Aplastic Anemia. Blood Research. 38(1). 1–7.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lowell L. Hart Breakdown of academic impact, for papers by Hiroshi Nokihara Breakdown of academic impact, for papers by Renato Martins Breakdown of academic impact, for papers by Mircea Dediu Breakdown of academic impact, for papers by M. Pérol Breakdown of academic impact, for papers by Wilfried Eberhardt Breakdown of academic impact, for papers by Haruyasu Murakami Breakdown of academic impact, for papers by Eng Huat Tan Breakdown of academic impact, for papers by Mark S. Huberman Breakdown of academic impact, for papers by Patrick M. Forde
Rankless by CCL
2026